Regina is a Managing Director at Angelini Ventures leading their biotech investment activities and representing Angelini Ventures on the Boards of ADCytherix, Nuclidium and a stealth Boston-based rare disease company. Prior, she was the Managing Partner at Wellington Partners Life Sciences (WPLS) and represented the WPLS funds on the Boards of Minervax, Seamless, Sidekick Health, SNIPR Biome, and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), invested in Themis Medical (acquired by MSD). In addition, she serves on the Board of the BII BioInnovation Institute and is a member of the advisory group for KfW Capital and the SME council of the German Ministry of Economics BMWK. 

Before this role, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star, and Jenavalve, and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (became part of Horizon Pharma NASDAQ: HRZN), Shanghai-based Novamed, and has been an external director at GSK‘s Respiratory TA Board. Before, Regina was part of Apax Partners, where she invested in Genmab and Silence Therapeutics, and at McKinsey. In the 90s, Regina worked as post-doctoral researcher in Sir Gregory Winter‘s lab at the MRC in Cambridge, UK and holds a Ph.D. in biochemistry.